 

Active Ingredient: Amcinonide 

 

Dosage Form; Route: Lotion; topical 

 

Recommended Studies: Two studies 

 

1. Type of study: Pilot Vasoconstrictor Study 


Design: Pilot dose duration-response study using the reference product 

Strength: 0.1% 

Subjects: Healthy males and females (non-pregnant, non-lactating), general population 
Additional comments: 1. Female subjects should not be pregnant or lactating, and if 
applicable, should practice abstention or contraception during the study. 2. Refer to the 
guidance “Topical Dermatological Corticosteroids: In Vivo Bioequivalence” available 
at: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070234.pdf. 

 

 

2. Type of study: Pivotal Vasoconstrictor Study 


Design: Pivotal in vivo bioequivalence study 

Strength: 0.1% 

Subjects: Healthy males and females (non-pregnant, non-lactating), general population 

Additional comments: See comments above. 

 

 

Analytes to measure (in appropriate biological fluid): Not applicable 

Bioequivalence based on (90% CI): Pivotal Vasoconstrictor Study 

 

Waiver request of in vivo testing: Not applicable 

 

Dissolution test method and sampling times: Not applicable 


